Investing long-term in the cell & gene therapies of the future

David McCall, Senior Editor, Cell & Gene Therapy Insights, speaks to Geeta Vemuri, Founder and Managing Partner, Agent Capital

Dr Geeta Vemuri is Founder and Managing Partner at Agent Capital. Geeta leads and oversees all Agent Capital activities, including portfolio management, new investments and operations activities. Prior to Agent Capital, Dr. Vemuri was the Managing Partner of Baxter Ventures and the Managing Partner of Baxalta Ventures, where she led each corporate venture capital arm with more than US $300 million under management. Prior to Baxter, Dr Vemuri was a Partner at Quaker Partners where she focused on biotech and healthcare investments. Dr Vemuri has served on the board of a variety of companies, including Cempra (until its IPO and Dr Vemuri’s departure in 2011), Covagen (acq. by J&J), Gadeta (acq. by Gilead), Naurex (acq. by Allergan), Ocular Therapeutix, Protez Pharmaceuticals (acq. by Novartis), Syntimmune (acq. by Alexion), and True North Therapeutics (acq. By Bioverativ/Sanofi), among others. Dr Vemuri received a PhD in biochemistry from Indian Institute of Sciences and an MBA from The Wharton School at the University of Pennsylvania.

Please enter your email to access content Read now